These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 28139897)

  • 1. Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
    Gesheff T; Barbour C
    J Am Assoc Nurse Pract; 2017 Feb; 29(2):104-115. PubMed ID: 28139897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of prasugrel in the management of acute coronary syndromes: a systematic review.
    Spartalis M; Tzatzaki E; Spartalis E; Damaskos C; Athanasiou A; Moris D; Politou M
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4733-4743. PubMed ID: 29131238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
    Roffman DS
    J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
    Gunarathne A; Hussain S; Gershlick AH
    Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1215-1226. PubMed ID: 27701930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
    Vengoechea F
    Hosp Pract (1995); 2014 Aug; 42(3):33-47. PubMed ID: 25255405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
    Sheikh Rezaei S; Geroldinger A; Heinze G; Reichardt B; Wolzt M
    Int J Cardiol; 2017 May; 235():61-66. PubMed ID: 28262344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
    Golino P
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
    Esteve-Pastor MA; Ruíz-Nodar JM; Orenes-Piñero E; Rivera-Caravaca JM; Quintana-Giner M; Véliz-Martínez A; Tello-Montoliu A; PerniasEscrig V; Sandín Rollán M; Vicente-Ibarra N; MacíasVillanego MJ; Candela Sánchez E; Carrillo Alemán L; Lozano T; Valdés M; Marín F
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):57-65. PubMed ID: 28789568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
    Qutub MA; Chong AY; So DY
    Can J Cardiol; 2015 Dec; 31(12):1481-4. PubMed ID: 26243350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.